Maralixibat is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Maralixibat directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Maralixibat remains protective as scientific knowledge develops.
Occupational exposure monitoring for Maralixibat validates that engineering controls achieve the OEL in worker breathing zones during manufacturing, dispensing, and sampling operations. Personal air sampling during representative manufacturing tasks—including powder dispensing, granulation, tableting, and equipment cleaning—provides the primary measure of control effect
